Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activated T cells are T lymphocytes that have encountered their specific antigen presented by an antigen-presenting cell and received necessary co-stimulatory signals. Upon activation, they undergo clonal expansion and differentiate into effector subsets with specialized functions—such as helper functions for B-cell antibody production or direct cytotoxicity against infected/cancerous cells. Activation is marked by upregulation of surface markers including CD69, CD25, and HLA‑DR. While essential for adaptive immunity against infections and tumors, dysregulated activated T-cell responses can drive autoimmunity or excessive inflammation. Importantly, "activated T cell" refers to a cellular state rather than a discrete molecular target; thus it is not considered a canonical therapeutic target like an individual receptor or enzyme.
Mechanisms relate to modulation of activation/proliferation/apoptosis via signaling pathways—e.g., calcineurin inhibitors block IL‑2 production in activated T cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activated T cell.